{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:37Z","timestamp":1790734777044,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clinthera.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T00:51:20Z","timestamp":1545612680000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview"],"prefix":"10.1016","volume":"41","author":[{"given":"Stefan Mark","family":"Nidorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Lindsay","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.11.016_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.116.301313","article-title":"Inflammation and immunity in diseases of the arterial tree: players and layers","volume":"116","author":"Libby","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2018.11.016_bib3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","article-title":"Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995","volume":"94","author":"Davies","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.11.016_bib4","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/01.CIR.91.11.2844","article-title":"Molecular bases of the acute coronary syndrome","volume":"91","author":"Libby","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2018.11.016_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ncpcardio0074","article-title":"C-reactive protein comes of age","volume":"2","author":"Verma","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"9709","key":"10.1016\/j.clinthera.2018.11.016_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.11.016_bib7","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2018.11.016_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2018.11.016_bib9","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"Pravastatin or atorvastatin Evaluation and infection therapy-Thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11883-012-0295-3","article-title":"Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?","volume":"15","author":"Ridker","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2018.11.016_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2018.11.016_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2018.11.016_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10118","key":"10.1016\/j.clinthera.2018.11.016_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.11.016_bib16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib17","series-title":"Ilaris (Canakinumab): Common Drug Review. Canadian Agency for Drugs and Technologies in Health","year":"2016"},{"key":"10.1016\/j.clinthera.2018.11.016_bib18","unstructured":"FDA Panel Rejects gout drug on safety concerns [WebMD website]. Available at: https:\/\/www.webmd.com. Accessed December 31, 2017."},{"key":"10.1016\/j.clinthera.2018.11.016_bib19","author":"Bell"},{"key":"10.1016\/j.clinthera.2018.11.016_bib20","article-title":"CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events","author":"Ridker","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib21","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2018.11.016_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1074248413499972","article-title":"Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease","volume":"19","author":"Nidorf","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.11.016_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacl.2010.03.003","article-title":"Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation","volume":"4","author":"Abela","year":"2010","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-041015-055539","article-title":"Crystal formation in inflammation","volume":"34","author":"Franklin","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2016.09.019","article-title":"Complement activation by cholesterol crystals triggers a subsequent cytokine response","volume":"84","author":"Niyonzima","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib26","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.4049\/jimmunol.1302484","article-title":"Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release","volume":"192","author":"Samstad","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2015.05.038","article-title":"The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis","volume":"241","author":"Hovland","year":"2015","journal-title":"Atherosclerosis"},{"issue":"7293","key":"10.1016\/j.clinthera.2018.11.016_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2018.11.016_bib29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/eurheartj\/ehv653","article-title":"Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque","volume":"37","author":"Janoudi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2018.11.016_bib30","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMra1601611","volume":"374","author":"Mulay","year":"2016","journal-title":"Crystallopathies N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib31","unstructured":"Colchicine [highlights of prescribing information]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022352s017lbl.pdf. Accessed January 4, 2018."},{"key":"10.1016\/j.clinthera.2018.11.016_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/1755-5922.12226","article-title":"Colchicine for prevention and treatment of cardiac diseases: a meta-analysis","volume":"35","author":"Papageorgiou","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2018.11.016_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Mart\u00ednez","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2018.11.016_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.11.016_bib35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clinthera.2018.11.016_bib36","first-page":"64","article-title":"Effect of colchicine on complement activity in familial Mediterranean fever","volume":"1","author":"Mkrtchyan","year":"2006","journal-title":"J\u00a0Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1083\/jcb.71.1.182","article-title":"Effect of colchicine on rat mast cells","volume":"71","author":"Lagunoff","year":"1976","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.V74594","article-title":"Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation","volume":"7","author":"Perico","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0008-8749(83)90023-0","article-title":"Metabolic and morphologic effects of colchicine on human T-lymphocyte expression of Fc mu and Fc gamma receptors","volume":"77","author":"Ercolani","year":"1983","journal-title":"Cell Immunol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10753-015-0237-7","article-title":"Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects [Erratum in: inflammation. 2016;39:501]","volume":"39","author":"Shah","year":"2016","journal-title":"Inflammation"},{"key":"10.1016\/j.clinthera.2018.11.016_bib41","first-page":"92","article-title":"Growth-inhibiting effect of colchicine on cultured vascular wall myocytes from arteriosclerotic lesions [in German]","volume":"81","author":"Bauriedel","year":"1992","journal-title":"Zeitschrift fur Kardiologie"},{"key":"10.1016\/j.clinthera.2018.11.016_bib42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1302\/0301-620X.83B6.0830912","article-title":"The inhibitory effects of colchicine on cell proliferation and mineralisation in culture","volume":"83-B","author":"Salai","year":"2001","journal-title":"J\u00a0Bone Joint Surg [Br]"},{"key":"10.1016\/j.clinthera.2018.11.016_bib43","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2 Pt 2","key":"10.1016\/j.clinthera.2018.11.016_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilisation in acute coronary syndrome patients\u2014a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.clinthera.2018.11.016_bib45","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2018.11.016_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinthera.2018.07.023","article-title":"The role of colchicine in acute coronary syndromes","volume":"41","author":"Vaidya","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.11.016_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinthera.2018.09.011","article-title":"Colchicine in stable coronary artery disease","volume":"41","author":"Fiolet","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.11.016_bib49","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.amjmed.2015.02.020","article-title":"Colchicine toxicity: an exaggerated reality?","volume":"128","author":"Solak","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2018.11.016_bib50","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","article-title":"Colchicine toxicity in end-stage renal disease patients: a case-control study","volume":"21","author":"Solak","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2018.11.016_bib51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/mus.20135","article-title":"Cytoskeletal myotoxicity from simvastatin and colchicine","volume":"30","author":"Baker","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2018.11.016_bib52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818305964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818305964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:25Z","timestamp":1758963025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818305964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0149291818305964"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.11.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734702884.793563072","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}